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Antiviral prostanoid libraries
The prostaglandin family constitutes one of the most pharmacologically active low molecular
weight chemical classes in existence. A library of prostanoid analogues has been prepared on a
soluble polymer support and used to find novel inhibitors of a herpes family virus (Soluble-
polymer supported synthesis of a prostanoid library: identification of antiviral activity, K.J. Lee
et al., Org. Lett., 1, (1999), 1859-1862).
A ‘parallel pool’ library strategy was employed in which small pools of compounds were
modified through a number of different functionalisation reactions. Starting with the enone (i)
attached to a soluble polystyrene support, a number of different ω- and α-chains were added
to generate the library (ii). Cleavage of the products from the support with fluoride ions
permitted biological evaluation of the library pools, and deconvolution of active pools gave the
identity of active single analogues.
The library of prostanoids was screened for their ability to inhibit the replication of murine
cytomegalovirus (CMV), and the analogue (iii) was discovered as the most potent. Although
an order of magnitude less potent than ganciclovir, the most frequently used anti-CMV agent,
this level of activity has encouraged the preparation of other structurally related prostanoids in
a second generation library to further the search for more active agents.
--------------------------------------------------------------------------------------------------------------
Cysteine protease libraries
Cysteine proteases are characterised by the presence of a key nucleophilic cysteine residue in
the active site of the enzyme that attacks the carbonyl of the hydrolysed substrate amide bond.
Various cysteine proteases are known to have physiological functions that make them suitable
as targets for pharmacological intervention. Examples include calpains implicated in
neurodegeneration, cathepsin K linked to osteoporosis and caspases which are possibly
involved in apoptosis.
Various mechanism-based inhibitors have been designed, many of which depend on a
electrophilic group such as a carbonyl or Michael acceptor that can covalently link to the
nucleophilic thiol group of the critical cysteine. A recent publication describes a versatile route
to ketone-based cysteine protease inhibitors that permits maximal variation of the ketone
structure (General solid-phase method for the preparation of mechanism-based cysteine
protease inhibitors, A. Lee et al., J. Am. Chem. Soc., 121, (1999), 9907-9914).
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A chloromethyl ketone, readily prepared in one pot from N-protected amino acids, was linked
to the solid support by reaction with a hydrazine linker. The tethered carbazate (iv) could then
be derivatised by nucleophilic displacement of the chloride, and further functionalisation of the
deprotected amine. A range of products (v) can be made, without racemisation of the α-chiral
centre, and ultimately liberated from the solid support in 40 to 100% overall yields. Library
preparation using this methodology is currently ongoing and the products will be evaluated
against representative cysteine proteases.
--------------------------------------------------------------------------------------------------------------
Orally active GPIIb/IIIa antagonists
Several serious cardiovascular conditions such as unstable angina and myocardial infarction
are associated with platelet aggregation, atherosclerotic plaque formation and ultimately,
thrombosis. In the process of thrombus formation, the final critical step is the adherence of the
protein fibrinogen to the activated membrane-bound glycoprotein IIb/IIIa. Compounds that
can compete with fibrinogen for the platelet glycoprotein receptor are potential antithrombotic
agents. In the search for orally active agents that have the potential to be used for chronic
cardiovascular care, a group from the R.W. Johnson Pharmaceutical Research Institute have
used combinatorial chemistry to optimise a prototype fibrinogen receptor antagonist (Potent,
orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity
studies leading to the discovery of RWJ-53308. W.J. Hoekstra et al., J. Med. Chem. 42,
(1999), 5254-5265).
Solid-phase parallel synthesis, employed in the preparation of around 250 analogues of
compound (vi), led to the discovery of RWJ-53308 (vii). This compound is an active anti-
platelet agent that can be administered both intravenously and orally, and which has a good
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duration of action. The compound has been successfully progressed through human phase II
clinical trials.
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